Privia Health Group, Inc. (NASDAQ:PRVA) Receives $27.62 Consensus Target Price from Brokerages

Shares of Privia Health Group, Inc. (NASDAQ:PRVA) have been assigned an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $26.58.

PRVA has been the subject of several research analyst reports. Truist Financial decreased their target price on Privia Health Group from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. TD Cowen dropped their target price on shares of Privia Health Group from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Friday, March 1st. Evercore ISI decreased their price target on shares of Privia Health Group from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Wednesday, February 28th. Canaccord Genuity Group dropped their price objective on Privia Health Group from $41.00 to $37.00 and set a “buy” rating on the stock in a research note on Tuesday, March 19th. Finally, Citigroup started coverage on Privia Health Group in a research report on Monday, April 22nd. They set a “buy” rating and a $25.00 target price for the company.

Insider Activity at Privia Health Group

In other Privia Health Group news, EVP Thomas Bartrum sold 2,252 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total transaction of $41,481.84. Following the transaction, the executive vice president now directly owns 103,862 shares in the company, valued at $1,913,138.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Privia Health Group news, EVP Thomas Bartrum sold 2,252 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $18.42, for a total transaction of $41,481.84. Following the sale, the executive vice president now owns 103,862 shares in the company, valued at approximately $1,913,138.04. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Parth Mehrotra sold 12,219 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total value of $225,073.98. Following the sale, the chief executive officer now directly owns 261,640 shares in the company, valued at approximately $4,819,408.80. The disclosure for this sale can be found here. Insiders have sold a total of 31,783 shares of company stock worth $582,886 over the last three months. 14.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Privia Health Group

Several institutional investors have recently bought and sold shares of PRVA. Covestor Ltd boosted its stake in shares of Privia Health Group by 8.3% during the 3rd quarter. Covestor Ltd now owns 6,703 shares of the company’s stock valued at $154,000 after buying an additional 514 shares during the last quarter. Yousif Capital Management LLC grew its holdings in Privia Health Group by 1.1% during the 4th quarter. Yousif Capital Management LLC now owns 52,628 shares of the company’s stock worth $1,212,000 after acquiring an additional 563 shares in the last quarter. New York State Common Retirement Fund increased its position in shares of Privia Health Group by 2.7% in the 3rd quarter. New York State Common Retirement Fund now owns 27,966 shares of the company’s stock worth $643,000 after purchasing an additional 737 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Privia Health Group by 9.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 8,970 shares of the company’s stock valued at $176,000 after buying an additional 756 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its position in shares of Privia Health Group by 0.9% during the 3rd quarter. Glenmede Trust Co. NA now owns 107,711 shares of the company’s stock valued at $2,477,000 after acquiring an additional 976 shares in the last quarter. 94.48% of the stock is currently owned by hedge funds and other institutional investors.

Privia Health Group Trading Up 0.9 %

NASDAQ PRVA opened at $19.25 on Friday. Privia Health Group has a 12 month low of $17.54 and a 12 month high of $30.15. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of 101.32, a PEG ratio of 2.56 and a beta of 0.81. The company’s 50 day moving average is $19.61 and its two-hundred day moving average is $21.06.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings data on Tuesday, February 27th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). Privia Health Group had a net margin of 1.39% and a return on equity of 3.97%. The company had revenue of $440.80 million for the quarter, compared to the consensus estimate of $425.81 million. During the same quarter in the previous year, the business earned $0.14 EPS. The company’s quarterly revenue was up 21.0% on a year-over-year basis. Sell-side analysts forecast that Privia Health Group will post 0.26 EPS for the current year.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.